[1S-(1α,3aβ,7aα)]-octahydro-7a-methyl-1-[5-methyl-1-[4-methyl-4-[(trimethylsilyl)oxy]pentyl]-5-[(trimethylsilyl)oxy]hexyl]-4H-inden-4-one | 215257-71-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: [1S-(1α,3aβ,7aα)]-octahydro-7a-methyl-1-[5-methyl-1-[4-methyl-4-[(trimethylsilyl)oxy]pentyl]-5-[(trimethylsilyl)oxy]hexyl]-4H-inden-4-one
• 英文别名: [1R-(1α,3aβ,4α,7aα)]octahydro-7a-methyl-1-[5-methyl-1-[4-methyl-4-[(trimethylsilyl) oxy]pentyl]-5-[(trimethylsilyl)oxy]hexyl]-4H-inden-4-one；[1R-(1α,3aβ,7aα)]octahydro-7a-methyl-1-[5-methyl-1-[4-methyl-4-[(trimethylsilyl)oxy]pentyl]-5-[(trimethylsilyl)oxy]hexyl]-4H-inden-4-one；(1R,3aR,7aR)-1-[2,10-dimethyl-2,10-bis(trimethylsilyloxy)undecan-6-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-one
• CAS: 215257-71-9
• 化学式: C₂₉H₅₈O₃Si₂
• 分子量: 510.949
• InChiKey: MJDVUKSWHVLPSL-BEYSDYMESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.99
• 重原子数：
  34
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [1S-(1α,3aβ,7aα)]-octahydro-7a-methyl-1-[5-methyl-1-[4-methyl-4-[(trimethylsilyl)oxy]pentyl]-5-[(trimethylsilyl)oxy]hexyl]-4H-inden-4-one 在 正丁基锂 、 四丁基氟化铵 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 17.12h， 生成 Ro 27-2310
  参考文献：
  名称：

  Characterization of a Novel Analogue of 1α,25(OH)₂-Vitamin D₃ with Two Side Chains:  Interaction with Its Nuclear Receptor and Cellular Actions

  摘要：

  The hormone 1 alpha,25(OH)(2)-vitamin D-3 (125D) binds to its nuclear receptor (VDR) to stimulate gene transcription activity. Inversion of configuration at C-20 of the side chain to generate 20-epi-1 alpha,25(OH)(2)Da (20E-125D) increases transcription 200-5000-fold over 125D with its 20-normal (20N) side chain. This enhancement has been attributed to the VDR ligand-binding domain (LBD) having different contact sites for 20N and 20E side chains that generate different VDR conformations. We synthesized 1 alpha,25-dihydroxy-21-(3-hydroxy-3-methylbutyl) vitamin D-3 (Gemini) with two six-carbon side chains (both 20N and 20E orientations). Energy minimization calculations indicate the Gemini side chain possesses significantly more energy minima than either 125D or 20E-125D (2346, 207, and 127 minima, respectively). We compared activities of 125D, 20E-125D, and Gemini, respectively,in several assays: binding to wild-type (100%, 147%, and 38%)and C-terminal-truncated mutant VDR; transcriptional activity (of the transfected osteopontin promoter in ROS 17/2.8 cells: ED50 10, 0.005, and 1.0 nM) mediation of conformational changes in VDR assessed by protease clipping major trypsin-resistant fragment of 34, 34, and 28 kDa). For inhibition of cellular clonal growth of human leukemia (HL-60) and breast cancer (MCF7) cell lines, the ED50(125D)/ED50(Gem) was respectively 380 and 316. We conclude that while Gemini readily binds to the VDR and generates unique conformational changes, none of them is able to permit a superior gene transcription activity despite the presence of a 20E side chain.

  DOI：

  10.1021/jm0000160
• 作为产物：
  描述：

  艾地骨化醇起始原料杂质1 在 palladium on activated charcoal 重铬酸吡啶 、 六氟合硅酸 、 potassium tert-butylate 、 氢气 、 二氯乙基铝 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 、 乙酸乙酯 、 乙腈 为溶剂， 反应 57.75h， 生成 [1S-(1α,3aβ,7aα)]-octahydro-7a-methyl-1-[5-methyl-1-[4-methyl-4-[(trimethylsilyl)oxy]pentyl]-5-[(trimethylsilyl)oxy]hexyl]-4H-inden-4-one
  参考文献：
  名称：

  Characterization of a Novel Analogue of 1α,25(OH)₂-Vitamin D₃ with Two Side Chains:  Interaction with Its Nuclear Receptor and Cellular Actions

  摘要：

  The hormone 1 alpha,25(OH)(2)-vitamin D-3 (125D) binds to its nuclear receptor (VDR) to stimulate gene transcription activity. Inversion of configuration at C-20 of the side chain to generate 20-epi-1 alpha,25(OH)(2)Da (20E-125D) increases transcription 200-5000-fold over 125D with its 20-normal (20N) side chain. This enhancement has been attributed to the VDR ligand-binding domain (LBD) having different contact sites for 20N and 20E side chains that generate different VDR conformations. We synthesized 1 alpha,25-dihydroxy-21-(3-hydroxy-3-methylbutyl) vitamin D-3 (Gemini) with two six-carbon side chains (both 20N and 20E orientations). Energy minimization calculations indicate the Gemini side chain possesses significantly more energy minima than either 125D or 20E-125D (2346, 207, and 127 minima, respectively). We compared activities of 125D, 20E-125D, and Gemini, respectively,in several assays: binding to wild-type (100%, 147%, and 38%)and C-terminal-truncated mutant VDR; transcriptional activity (of the transfected osteopontin promoter in ROS 17/2.8 cells: ED50 10, 0.005, and 1.0 nM) mediation of conformational changes in VDR assessed by protease clipping major trypsin-resistant fragment of 34, 34, and 28 kDa). For inhibition of cellular clonal growth of human leukemia (HL-60) and breast cancer (MCF7) cell lines, the ED50(125D)/ED50(Gem) was respectively 380 and 316. We conclude that while Gemini readily binds to the VDR and generates unique conformational changes, none of them is able to permit a superior gene transcription activity despite the presence of a 20E side chain.

  DOI：

  10.1021/jm0000160

文献信息

• [3,3]-Sigmatropic rearrangement mediated synthesis of chiral building blocks for the preparation of Gemini and its analogs
  作者：Gonzalo Pazos、Manuel Pérez、Zoila Gándara、Generosa Gómez、Yagamare Fall

  DOI：10.1039/c6ra08789b

  日期：——

  A novel synthetic methodology for the preparation of Gemini vitamin D3 analogs has been developed. Our procedure uses a key sigmatropic rearrangement which allows control over the C-20 stereochemistry, providing a versatile method to introduce novel side-chains to the vitamin D scaffold giving access to new analogs with potentially interesting biological properties.

  已经开发了用于制备双子座维生素D 3类似物的新颖的合成方法。我们的程序使用关键的σ重排，可以控制C-20立体化学，提供了一种将新的侧链引入维生素D支架的通用方法，从而可以使用具有潜在有趣生物学特性的新类似物。
• Vitamin D.sub.3 analogs with bis C-20 side chains
  申请人：Synttex (U.S.A.) Inc.

  公开号：US06030962A1

  公开（公告）日：2000-02-29

  This invention provides Vitamin D.sub.3 analogs of the Formula I ##STR1## wherein: X is H.sub.2 or CH.sub.2 ; Y is hydrogen, hydroxy or fluorine; Z is hydroxy; R.sub.1 and R.sub.2 are a (C.sub.1 -C.sub.4) alkyl or fluoroalkyl, or R.sub.1 and R.sub.2 together with C.sub.25 form a (C.sub.3 -C.sub.6) cycloalkyl or cyclofluoroalkyl; R.sub.3 and R.sub.4 are a (C.sub.1 -C.sub.4) alkyl or fluoroalkyl, or R.sub.3 and R.sub.4 together with C.sub.25, form a (C.sub.3 -C.sub.6)cycloalkyl or cyclofluoroalkyl; A is a single bond or a double bond; B.sub.1 is a single bond, an E-double bond, a Z-double bond or a triple bond; and B.sub.2 is a single bond, an E-double bond, a Z-double bond or a triple bond; and prodrugs thereof, intermediates and methods for preparation of these analogs, pharmaceutical compositions containing such analogs and methods for treatment of osteoporosis, hyperparathyroidism and autoimmune diseases.

  本发明提供了公式I的维生素D.sub.3类似物，其中：X是H.sub.2或CH.sub.2; Y是氢、羟基或氟; Z是羟基; R.sub.1和R.sub.2是(C.sub.1-C.sub.4)烷基或氟代烷基，或者R.sub.1和R.sub.2与C.sub.25一起形成(C.sub.3-C.sub.6)环烷基或环氟代烷基; R.sub.3和R.sub.4是(C.sub.1-C.sub.4)烷基或氟代烷基，或者R.sub.3和R.sub.4与C.sub.25一起形成(C.sub.3-C.sub.6)环烷基或环氟代烷基; A是单键或双键; B.sub.1是单键、E-双键、Z-双键或三键; B.sub.2是单键、E-双键、Z-双键或三键; 以及其前药、中间体和制备这些类似物的方法，含有这些类似物的制药组合物以及治疗骨质疏松症、甲状旁腺功能亢进和自身免疫性疾病的方法。
• WO2008/43857
  申请人：——

  公开号：——

  公开（公告）日：——
• WO2008/34908
  申请人：——

  公开号：——

  公开（公告）日：——
• Characterization of a Novel Analogue of 1α,25(OH)₂-Vitamin D₃ with Two Side Chains:  Interaction with Its Nuclear Receptor and Cellular Actions
  作者：Anthony W. Norman、Percy S. Manchand、Milan R. Uskokovic、William H. Okamura、Janet A. Takeuchi、June E. Bishop、Jun-Iichi Hisatake、H. Phillip Koeffler、Sara Peleg

  DOI：10.1021/jm0000160

  日期：2000.7.1

  The hormone 1 alpha,25(OH)(2)-vitamin D-3 (125D) binds to its nuclear receptor (VDR) to stimulate gene transcription activity. Inversion of configuration at C-20 of the side chain to generate 20-epi-1 alpha,25(OH)(2)Da (20E-125D) increases transcription 200-5000-fold over 125D with its 20-normal (20N) side chain. This enhancement has been attributed to the VDR ligand-binding domain (LBD) having different contact sites for 20N and 20E side chains that generate different VDR conformations. We synthesized 1 alpha,25-dihydroxy-21-(3-hydroxy-3-methylbutyl) vitamin D-3 (Gemini) with two six-carbon side chains (both 20N and 20E orientations). Energy minimization calculations indicate the Gemini side chain possesses significantly more energy minima than either 125D or 20E-125D (2346, 207, and 127 minima, respectively). We compared activities of 125D, 20E-125D, and Gemini, respectively,in several assays: binding to wild-type (100%, 147%, and 38%)and C-terminal-truncated mutant VDR; transcriptional activity (of the transfected osteopontin promoter in ROS 17/2.8 cells: ED50 10, 0.005, and 1.0 nM) mediation of conformational changes in VDR assessed by protease clipping major trypsin-resistant fragment of 34, 34, and 28 kDa). For inhibition of cellular clonal growth of human leukemia (HL-60) and breast cancer (MCF7) cell lines, the ED50(125D)/ED50(Gem) was respectively 380 and 316. We conclude that while Gemini readily binds to the VDR and generates unique conformational changes, none of them is able to permit a superior gene transcription activity despite the presence of a 20E side chain.